Blockade of LTB(4) /BLT(1) pathway improves CD8(+) T-cell-mediated colitis

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Leukotriene B4 (LTB(4)) promotes T cell migration via the BLT(1) receptor.
• Cytotoxic CD8(+) T lymphocytes (CTL) play a role in T cell-mediated colitis.
• The LTB(4) antagonist CP-105,693 selectively targets the BLT(1) receptor.

Purpose of the Study:

• To investigate if a selective LTB(4) receptor antagonist could prevent colitis induced by specific CTL.
• To evaluate the therapeutic potential of BLT(1) receptor blockade in T cell-mediated intestinal inflammation.

Main Methods:

• Virus-specific colitis was induced in mice using viral peptide-pulsed dendritic cells and intrarectal peptide challenge.
• CTL priming was assessed via IFN-γ ELISPOT and in vivo CTL assays.
• Mice were treated with a selective LTB(4) receptor antagonist before colitis induction.

Main Results:

• Dendritic cell immunization successfully primed antigen-specific CD8(+) CTL.
• Intrarectal peptide challenge induced severe colitis with significant CTL infiltration in the colon.
• Treatment with the LTB(4) receptor antagonist significantly reduced colitis severity and effector cell recruitment.

Conclusions:

• IFN-γ-producing cytotoxic CD8(+) CTL are key mediators of viral antigen-induced colitis.
• Blocking the LTB(4)/BLT(1) pathway with a selective antagonist attenuates colitis.
• LTB(4) receptor antagonists show therapeutic promise for CD8(+) T-cell-mediated intestinal inflammation.